NASDAQ:PAVM
PAVmed Inc.
PAVmed Inc.'s revenue fell 97.6% in fiscal 2025 to $71,000 while operating margin fell to −30712.7%, its lowest in 5 years. Free cash flow was −$5.2M, −7376.1% of revenue, and the diluted share count fell 69.2%.Summary generated from PAVmed Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$71,000
Revenue growth−97.6%
Revenue, 5-yr CAGRn/a
Gross margin−207.0%
Operating margin−30712.7%
Net margin564.8%
ROICn/a
Return on equity2.5%
Debt / equityn/a
Free cash flow−$5.2M
FCF margin−7376.1%
Share count change−69.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 3 | 3 | 0 |
| Operating income | −54 | −91 | −69 | −44 | −22 |
| Net income | −50 | −89 | −64 | 40 | 0 |
| Free cash flow | −42 | −73 | −52 | −34 | −5 |
Recent filings
- 8-KEntry into a material agreement
Sep 10, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KDirector or officer change
Jun 24, 2026 - 8-KResults of operations and financial condition
May 15, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - DEF 14AProxy statement
Apr 30, 2026 - 4Insider transaction report
Apr 13, 2026